Today, March 8, is the 100th anniversary of International Women’s Day, Here is a small sampling of initiatives by health organizations and healthcare leaders dedicated to treating, preventing, and increasing awareness of women’s cancers, and improving women’s health.
Cancer Network Editors
Esophageal cancer generally has a poor prognosis; while preoperative chemotherapy is recommended, tumors often do not respond to treatment.
In a population-based screening study of nearly 20,000 men in Rotterdam, men with baseline prostate-specific antigen (PSA) levels
Colorectal cancer is one of the most commonly diagnosed cancers in the US, and it is the second leading cause of cancer-related deaths. The risk of developing colorectal cancer increases with age.
An estimated 250 million people globally, and 25 million in the US, suffer from rare diseases. Clearly, because of their low incidence, rare cancers are difficult to study and pose challenges for detection, diagnosis, prognosis, and treatment.
Questions over safety in Delcath Systems' chemotherapy delivery system for melphalan in the treatment of liver tumors caused the FDA to issue a refusal-to-file letter.
The Swiss pharmaceutical company Roche and Roche Group member Genentech have announced that addition of bevacizumab (Avastin) to chemotherapy improved progression-free survival over chemotherapy alone in the phase III OCEANS ovarian cancer study, meeting the study’s primary endpoint.
The American Society for Radiation Oncology (ASTRO) has released guidelines for the use of radiation therapy in treating bone metastases; the guidelines are published in the International Journal of Radiation Oncology, Biology, Physics.
While more than 12 million people in the US are cancer survivors, an online survey conducted by the Oncology Nursing Society (ONS) has found that only about one-quarter of oncology nurses surveyed had a formal survivorship program in place at their institutions.
A team of researchers at Stony Brook University School of Medicine in New York published a paper in JAMA last week showing that patients who receive Avastin (bevacizumab), in combination with chemotherapy are at increased risk of side effects that may lead to death